All News

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Top articles in 2025 covered advancements in acute myeloid leukemia treatments, including allogeneic CAR T-cell therapy.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards.

Lerodalcibep-liga subcutaneous injection is now approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

Recent political shifts impacting health policy and access to care for millions dominated the news in 2025.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

From immunotherapy breakthroughs to early-stage scientific advances shaping the next generation of cancer care, these were the top oncology stories from AACR.

Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies.

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy.

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients.

Clascoterone 5% topical solution shows promise as a new treatment for male androgenetic alopecia, offering significant hair growth improvements with minimal side effects.

A recent study compares AI models DeepSeek-R1 and ChatGPT-4o in providing accurate, accessible information on urticaria, with DeepSeek showing superior performance.

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Eric H. Yang, MD, warns that lifetime cardiovascular risk for patients with breast cancer may exceed the general population as life expectancies grow, emphasizing the need for early intervention.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Artificial intelligence and lung cancer highlighted the top conference coverage from the Association of Cancer Care Centers Annual Meeting in Washington, DC.

Debra Patt, MD, PhD, MBA, MPH, spoke at SABCS about the importance of patient-investigator collaboration to enhance the clinical trial process.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

The oral medication could be used in gonorrhea that is resistant to antibiotics according to a new phase 3 clinical trial.

The novel biomarker APP performed comparably to Fibrosis-4 overall and showed improved cirrhosis detection in patients with diabetes.

Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.

Genetic risk models and variant tools help to guide intensive interventions for high-risk carriers and personalized management for others.

Adding ianalumab to eltrombopag significantly prolongs time to treatment failure, boosts 6-month response rates, and improves fatigue for adults with primary ITP.